证券代码：603739 证券简称：蔚蓝生物 公告编号：2025-022 青岛蔚蓝生物股份有限公司 2024年年度股东会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 | 1、出席会议的股东和代理人人数 | 192 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 163,833,460 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | 64.7489 | | 份总数的比例（%） | | (四) 表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次股东会由公司董事会召集，采用现场投票和网络投票相结合的方式召开。 (一) 股东会召开的时间：2025 年 5 月 16 日 (二) 股东会召开的地点：青岛市崂山区九水东路 596-1 号 蔚蓝生物创新园 B 座 多媒体会议室 (三) 出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： 现场会议由公司董事长陈刚先生主持。会议召 ...

北京海润天睿律师事务所 二〇二五年五月 关于青岛蔚蓝生物股份有限公司 2024 年年度股东会的 法律意见书 中国·北京 地址：朝阳区建外大街甲 14 号广播大厦 5 层、9 层、10 层、13 层、17 层 邮编：100022 电话：（010）65219696 传真：（010）88381869 北京海润天睿律师事务所 关于青岛蔚蓝生物股份有限公司 2024 年年度股东会的法律意见书 致：青岛蔚蓝生物股份有限公司 北京海润天睿律师事务所（以下简称"本所"）接受青岛蔚蓝生物股份有限 公司（以下简称"公司"）的委托，指派本所律师出席公司 2024 年年度股东会， 并依据《中华人民共和国公司法》（以下简称"《公司法》"）、《上市公司治理准则》 《公司章程》及其他相关法律、法规的规定，就公司本次股东会的召集、召开程 序、出席会议人员的资格、召集人资格、表决程序及表决结果等有关事宜出具本 法律意见书。 对本法律意见，本所律师声明如下： 本所及经办律师依据《证券法》《律师事务所从事证券法律业务管理办法》 和《律师事务所证券法律业务执业规则》等规定及本法律意见书出具日以前已经 发生或者存在的事实，严格履行了法定职责，遵循了勤 ...

Group 1 - The concept of ergothioneine has gained significant attention in the A-share market, with stocks related to this concept experiencing strong price increases [2][3] - Key stocks in the ergothioneine sector include Tuoxin Pharmaceutical and Chuaning Biological, both of which reached their daily limit up, while other companies like Bawei Co., Xianle Health, and Huaxi Biological also saw gains [2][3] - The chairman of Kelun Pharmaceutical, Liu Gexin, has endorsed the company's anti-aging product "ergothioneine capsules," claiming to have used the product for three years, which has contributed to the product's popularity [2][3] Group 2 - Kelun Pharmaceutical reported a revenue of 4.39 billion yuan in Q1, a year-on-year decline of 29.42%, with a net profit of 584 million yuan, down 43.07% [2][4] - The decline in revenue and profit is attributed to high base effects from the previous year and the impact of centralized procurement on the infusion business [2][4] - The company aims to establish a new subsidiary, Kelun Yongnian, to focus on the sales of ergothioneine products, indicating a strategic shift towards the health industry [3][4] Group 3 - There are 14 stocks in the A-share market related to ergothioneine, with Huadong Medicine, Kelun Pharmaceutical, and Chuaning Biological having the largest market capitalizations [4] - The average stock price increase for ergothioneine-related stocks this year is 19.16%, with Ruoyuchen leading with a 104.62% increase [4] - Half of the ergothioneine concept stocks reported positive net profits in Q1, with companies like Changshan Pharmaceutical turning losses into profits [4] Group 4 - There was a significant net inflow of capital into ergothioneine concept stocks today, with Chuaning Biological, Jindawei, and Kelun Pharmaceutical seeing the highest net inflows of 563 million yuan, 153 million yuan, and 129 million yuan respectively [5]

Core Viewpoint - Synthetic biology concept stocks are experiencing significant upward movement, with notable gains in several companies [1] Group 1: Company Performance - Chuaning Biological (301301) reached a 20% daily limit increase [1] - Bawi Co., Ltd. saw an increase of over 20% [1] - Toxin Pharmaceutical (301089) rose by more than 10% [1] - Jindawei (002626), Oukang Pharmaceutical, and Weilan Biological (603739) also experienced upward trends [1] Group 2: Market Activity - There is a notable influx of dark pool funds into these stocks [1]

A股生物医药板块盘初拉升，瑞普生物涨超8%，*ST贤丰涨超3.5%，科兴制药、东方生物、科前生物、 蔚蓝生物等跟涨。 ...

青岛蔚蓝生物股份有限公司 2024 年年度股东会 会议材料 二〇二五年五月十六日 | | | 青岛蔚蓝生物股份有限公司 2024 年年度股东会会议议程 一、会议召开的基本情况 （一）会议类型和届次：2024 年年度股东会 （二）会议召开时间、地点： 会议时间：2025 年 5 月 16 日 14 点 30 分 会议地点：青岛市崂山区九水东路 596-1 号蔚蓝生物创新园 B 座多媒体会 议室 为了维护青岛蔚蓝生物股份有限公司（以下简称"公司"）全体股东的合法 权益，确保股东会的正常秩序和议事效率，保证大会的顺利进行，根据中国证监 会《上市公司股东会规则》规定和《公司章程》《股东会议事规则》等相关法律 法规的规定，特制定本次股东会须知如下： （三）会议出席人员 二、会议议程 （五）与会代表休息（工作人员统计现场投票结果），等待接收网络投票结 果； （六）网络投票结果产生后，宣读投票结果和决议； （七）律师宣读本次股东会法律意见书，与会董事等人员在会议决议及记录 上签字； （八）宣布会议结束。 1、股东、股东代表 2、公司董事、监事和高级管理人员 3、公司聘请的律师 4、其他人员 （一）报告会议出席情况，宣布会议 ...

Core Insights - In 2024, the company achieved operating revenue of 1.32 billion yuan, a year-on-year increase of 10.16%, while net profit attributable to shareholders was 63 million yuan, a decline of 22.39% [1] - The decline in profit is attributed to increased depreciation expenses after the completion of the animal health industrial park, a 17.49% rise in management expenses, and a 46.48% increase in financial expenses due to interest expenses being recognized as costs [1] Enzyme Business - The enzyme business generated revenue of 505 million yuan in 2024, a year-on-year growth of 14.34%, becoming the main driver of the company's revenue growth [2] - The gross profit margin reached 63.69%, an increase of 2.89 percentage points, driven by continuous investment in technological innovation and optimization of production processes [2] - The company is expanding into various fields including industrial enzymes, food enzymes, and pharmaceutical enzymes, and has established an AI technology development laboratory to enhance R&D efficiency [2] Animal Health Products - Revenue from the animal health products business was 308 million yuan in 2024, a slight increase of 3.56%, but the gross profit margin fell to 33.51%, down 8.23 percentage points [3] - The decline in gross profit margin is primarily due to increased depreciation after the industrial park's completion, but long-term benefits are expected from improved product structure and quality [3] - The company plans to focus on biological products, particularly pig vaccines and imported generics, while also expanding into the pet medicine sector [3] Capacity and R&D Investment - With the increase in new capacity utilization and the gradual release of new products, the profitability of the animal health business is expected to recover [4] - The company invested 118 million yuan in R&D in 2024, a year-on-year increase of 6.81%, accounting for 8.95% of revenue, with 266 R&D personnel [4] - The company has established six technology centers and two key laboratories, with major projects expected to be operational by 2025, laying a foundation for future growth [4] Profit Forecast and Investment Recommendation - The expected EPS for 2025-2027 is projected to be 0.44 yuan, 0.51 yuan, and 0.60 yuan, corresponding to dynamic PE ratios of 29, 24, and 21 times, respectively, maintaining a "hold" rating [4]

特此公告。 青岛蔚蓝生物股份有限公司董事会 2025 年 5 月 1 日 本公司董事会及全体董事保证本公告内容不存在虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 为进一步加强与投资者的互动交流，青岛蔚蓝生物股份有限公司（以下简称 "公司"）将参加由青岛证监局指导，青岛市上市公司协会与深圳市全景网络有 限公司联合举办的"2025 年青岛辖区上市公司投资者网上集体接待日活动"，现 将相关事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （http://rs.p5w.net）；或关注微信公众号（名称：全景财经）；或下载全景路 演 APP,参与本次互动交流。活动时间为 2025 年 5 月 12 日（周一）15:00-17:00。 届时公司董事长兼总经理陈刚先生、董事兼财务总监乔丕远先生、董事会秘书姜 勇先生、独立董事林英庭先生、独立董事王京先生将以在线交流形式就公司治理、 发展战略、经营状况、融资计划、股权激励和可持续发展等投资者关注的问题与 投资者进行沟通与交流，欢迎广大投资者踊跃参与！ 证券代码：603739 证券简称：蔚蓝生物 公告编号：2 ...

Investment Rating - The report maintains a "Recommended" rating for the company, indicating a potential upside of over 15% relative to the benchmark index [6][8]. Core Views - The company experienced short-term pressure on performance, with a 10.16% year-on-year revenue growth to 1.32 billion yuan in 2024, but a 22.39% decline in net profit attributable to shareholders [3][4]. - The company is focusing on innovation and increasing R&D investment, which reached 118 million yuan in 2024, accounting for 8.95% of revenue, and is expected to drive long-term growth [5][6]. - The company has completed its capacity layout, enhancing multi-business synergy, with several projects operational by the end of 2024 [5]. Financial Performance Summary - In 2024, the company achieved revenue of 1.32 billion yuan, with a net profit of 63 million yuan, reflecting a decline in profitability due to increased competition and higher depreciation costs [3][4]. - For Q1 2025, the company reported revenue of 310 million yuan, a year-on-year increase of 8.16%, but a 24.73% decline in net profit [3][4]. - The company forecasts revenue growth rates of 10.2%, 8.4%, 8.9%, and 9.4% for the years 2024 to 2027, respectively [7][11]. Business Segment Performance - In 2024, the enzyme preparation segment generated 505 million yuan, the micro-ecology segment 193 million yuan, and the animal health products segment 308 million yuan, with respective gross margins of 63.69%, 37.29%, and 33.51% [4]. - For Q1 2025, the enzyme preparation segment achieved revenue of 120 million yuan, with a gross margin of 44.36% [4]. R&D and Innovation - The company has applied for 81 invention patents related to probiotics and has published 32 articles, enhancing its competitive strength in nutrition and health-related businesses [5][6]. - The integration of AI technology is expected to further strengthen the company's capabilities in product innovation and application design [5]. Future Earnings Forecast - The company is projected to achieve net profits of 74 million yuan in 2025, 81 million yuan in 2026, and 90 million yuan in 2027, with corresponding EPS of 0.29, 0.32, and 0.35 yuan [6][7].

青岛蔚蓝生物股份有限公司 关于获得新兽药注册证书的公告 本公司董事会及全体董事保证本公告内容不存在虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据《兽药管理条例》和《兽药注册办法》等的相关规定，经农业农村部审 查，批准青岛蔚蓝生物股份有限公司（以下简称"公司"）及全资子公司青岛康 地恩动物药业有限公司与其他单位联合申报的"非罗考昔咀嚼片"为二类新兽药， 批准公司全资子公司青岛康地恩动物药业有限公司与其他单位联合申报的"盐酸 聚六亚甲基双胍溶液"为三类新兽药，并于近日核发了《新兽药注册证书》（农 业农村部公告第 901 号）。 一、新兽药的基本信息 证券代码：603739 证券简称：蔚蓝生物 公告编号：2025-020 1、非罗考昔咀嚼片 新兽药名称：非罗考昔咀嚼片 研制单位：青岛蔚蓝生物股份有限公司、青岛康地恩动物药业有限公司、东 莞市东阳光动物保健药品有限公司、浙江海正动物保健品有限公司、江西瑞德制 药有限公司、湖北中博绿亚生物技术有限公司、四川吉星动物药业有限公司、河 北远征禾木药业有限公司、天津市中升挑战生物科技有限公司、江西邦诚动物药 业有限公司、内蒙古联邦动 ...